Our numbers are based on the following assumptions, taken as much as possible from the medical literature: the prevalence of prostate cancer that would be fatal within 10 years, if untreated, is 2%; the prevalence of prostate cancer that would not be fatal within 10 years is 20%; the sensitivity of a PSA screening test is 100% for the fatal form of cancer and 30% for the nonfatal form; treatment results in a 50% reduction in the chances of dying from an otherwise fatal cancer; and the chances of suffering erectile dysfunction or incontinence because of treatment is 58% [12–14]. Here, KLK3 is linked to prostate cancer.